

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

諾誠健華

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9969)

INSIDE INFORMATION ANNOUNCEMENT

LISTING OF RMB SHARES ON THE STAR MARKET

This announcement is made by InnoCare Pharma Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Company’s announcements dated 11 March 2021, 26 May 2021, 13 September 2021, 13 April 2022, 1 June 2022, 3 August 2022, 5 August 2022, 22 August 2022, 1 September 2022 and 8 September 2022 and the Company’s circulars dated 3 June 2021, 18 May 2022 and supplemental circular dated 6 June 2022 (the “**Circulars**”) in relation to, among others, the RMB Share Issue. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circulars.

The Board is pleased to announce that, the RMB Shares of the Company will be listed and become available for trading on the STAR Market of the SSE on 21 September 2022. Certain key information in respect of the RMB Share Issue is as follows:

Place of listing of the RMB Shares:	The STAR Market of the SSE
Date of listing of the RMB Shares:	21 September 2022
Stock abbreviation of the RMB Shares:	InnoCare (諾誠健華)
Stock code of the RMB Shares:	688428
Total number of issued shares of the Company immediately after the RMB Share Issue:	1,764,321,452 (including 1,499,673,235 Shares listed on The Stock Exchange of Hong Kong Limited and 264,648,217 RMB Shares)

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company. This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 20 September 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Shan Fu, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Dr. Zemin Jason Zhang, Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.